163 related articles for article (PubMed ID: 23770134)
21. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
22. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
23. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
24. The impact of symptom clusters on endocrine therapy adherence in patients with breast cancer.
Agnew S; Crawford M; MacPherson I; Shiramizu V; Fleming L
Breast; 2024 Jun; 75():103731. PubMed ID: 38599048
[TBL] [Abstract][Full Text] [Related]
25. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
26. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
Bright EE; Petrie KJ; Partridge AH; Stanton AL
Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
[TBL] [Abstract][Full Text] [Related]
27. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
28. Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer.
Lee JY; Min YH
BMC Womens Health; 2018 Mar; 18(1):48. PubMed ID: 29551094
[TBL] [Abstract][Full Text] [Related]
29. Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.
Sousa M; Peate M; Lewis C; Jarvis S; Willis A; Hickey M; Friedlander M
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12820. PubMed ID: 29337398
[TBL] [Abstract][Full Text] [Related]
30. A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy.
Pieters HC; Green E; Khakshooy S; Sleven M; Stanton AL
PLoS One; 2019; 14(1):e0210972. PubMed ID: 30703119
[TBL] [Abstract][Full Text] [Related]
31. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
32. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
33. Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
Doggrell SA
Breast Cancer Res Treat; 2011 Sep; 129(2):299-308. PubMed ID: 21594663
[TBL] [Abstract][Full Text] [Related]
34. Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
Tan EH; Wong ALA; Tan CC; Wong P; Tan SH; Ang LEY; Lim SE; Chong WQ; Ho J; Lee SC; Tai BC
Breast Cancer Res Treat; 2021 Aug; 188(3):779-788. PubMed ID: 33948777
[TBL] [Abstract][Full Text] [Related]
35. Beliefs and attitudes toward endocrine therapy in patients with hormone receptor-positive breast cancer.
Kim Y; Min YH; Lee SB
Health Care Women Int; 2021 Sep; 42(7-9):1086-1097. PubMed ID: 32886576
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
Clancy C; Lynch J; OConnor P; Dowling M
Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
[TBL] [Abstract][Full Text] [Related]
38. More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):998-1018. PubMed ID: 28940998
[TBL] [Abstract][Full Text] [Related]
39. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
